Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.

BACKGROUND Neuraminidase inhibitors (NAIs) play a key role in the management of influenza epidemics and pandemics. Given the novel pandemic influenza A(H1N1) (pH1N1) virus and the restricted number of approved anti-influenza drugs, evaluation of potential drug-resistant variants is of high priority. METHODS Recombinant pH1N1 viruses were generated by reverse genetics, expressing either the wild-type or any of 9 mutant neuraminidase (NA) proteins (N2 numbering: E119G, E119V, D198G, I222V, H274Y, N294S, S334N, I222V-H274Y, and H274Y-S334N). We evaluated these recombinant viruses for their resistance phenotype to 4 NAIs (oseltamivir, zanamivir, peramivir, and A-315675), NA enzymatic activity, and replicative capacity. RESULTS The E119G and E119V mutations conferred a multidrug resistance phenotype to many NAIs but severely compromised viral fitness. The oseltamivir- and peramivir-resistance phenotype was confirmed for the H274Y and N294S mutants, although both viruses remained susceptible to zanamivir. Remarkably, the I222V mutation had a synergistic effect on the oseltamivir- and peramivir-resistance phenotype of H274Y and compensated for reduced viral fitness, raising concerns about the potential emergence and dissemination of this double-mutant virus. CONCLUSIONS This study highlights the importance of continuous monitoring of antiviral drug resistance in clinical samples as well as the need to develop new agents and combination strategies.

[1]  G. Boivin,et al.  Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. Potier,et al.  Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. , 1979, Analytical biochemistry.

[3]  G. Boivin,et al.  Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. , 2008, Antiviral research.

[4]  A. Kelso,et al.  Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase Mutation , 2009, Journal of Virology.

[5]  G. Boivin,et al.  Treatment of respiratory virus infections , 2006, Antiviral Research.

[6]  M. Eichelberger,et al.  Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Update: influenza activity--United States. , 1986, MMWR. Morbidity and mortality weekly report.

[8]  R. Webster,et al.  Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo , 2007, Journal of Virology.

[9]  Yoshihiro Kawaoka,et al.  oseltamivir: descriptive study , 2022 .

[10]  Janet Daly,et al.  Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. , 2006, The Journal of antimicrobial chemotherapy.

[11]  P. Horby,et al.  A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. , 2010, The New England journal of medicine.

[12]  Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January 2010. , 2009, Releve epidemiologique hebdomadaire.

[13]  Alan J. Hay,et al.  Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants , 2008, Nature.

[14]  R. Webster,et al.  Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en , 1997, Journal of virology.

[15]  R. Saito,et al.  Rare Influenza A (H3N2) Variants with Reduced Sensitivity to Antiviral Drugs , 2010, Emerging infectious diseases.

[16]  T. Uyeki,et al.  Influenza estacional en adultos y niños—Diagnóstico, tratamiento, quimioprofilaxis y control de brotes institucionales: Guías de práctica clínica de la Sociedad de Enfermedades Infecciosas de Estados Unidos de América , 2009, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[17]  M. Saad,et al.  Possible Avian Influenza (H5N1) from Migratory Bird, Egypt , 2007, Emerging infectious diseases.

[18]  Guy Boivin,et al.  Impact of Neuraminidase Mutations Conferring Influenza Resistance to Neuraminidase Inhibitors in the N1 and N2 Genetic Backgrounds , 2006, Antiviral therapy.

[19]  Gerry Barber,et al.  Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[20]  L. Gubareva,et al.  Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. , 2003, The New England journal of medicine.

[21]  G. Boivin,et al.  Prophylactic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H274Y Neuraminidase Mutation , 2010, Antimicrobial Agents and Chemotherapy.

[22]  Yi Guan,et al.  Oseltamivir resistance during treatment of influenza A (H5N1) infection. , 2005, The New England journal of medicine.

[23]  I. Barr,et al.  In Vitro Generation of Neuraminidase Inhibitor Resistance in A(H5N1) Influenza Viruses , 2009, Antimicrobial Agents and Chemotherapy.

[24]  A. Moscona,et al.  Global transmission of oseltamivir-resistant influenza. , 2009, The New England journal of medicine.

[25]  Vasiliy P. Mishin,et al.  Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors , 2005, Antimicrobial Agents and Chemotherapy.

[26]  F. Hayden,et al.  Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. , 2001, The Journal of infectious diseases.

[27]  Hideo Goto,et al.  Avian flu: Isolation of drug-resistant H5N1 virus , 2005, Nature.

[28]  G. Ma,et al.  Improved and simplified recombineering approach for influenza virus reverse genetics , 2009, Journal of molecular and genetic medicine : an international journal of biomedical research.

[29]  F. Aoki,et al.  Influenza Virus Susceptibility and Resistance to Oseltamivir , 2005, Antiviral therapy.

[30]  L. Brammer,et al.  Update: influenza activity - United States, September 28, 2008--January 31, 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[31]  D. Mendel,et al.  Mechanism by Which Mutations at His274 Alter Sensitivity of Influenza A Virus N1 Neuraminidase to Oseltamivir Carboxylate and Zanamivir , 2002, Antimicrobial Agents and Chemotherapy.

[32]  Stefan Gravenstein,et al.  Influenza estacional en adultos y niños—Diagnóstico, tratamiento, quimioprofilaxis y control de brotes institucionales: Guías de práctica clínica de la Sociedad de Enfermedades Infecciosas de Estados Unidos de América , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Catherine Macken,et al.  Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use , 2006, Antimicrobial Agents and Chemotherapy.

[34]  Guy Boivin,et al.  Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. , 2009, The New England journal of medicine.

[35]  C. Cheung,et al.  Oseltamivir-Resistant Influenza A Pandemic (H1N1) 2009 Virus, Hong Kong, China , 2009, Emerging infectious diseases.

[36]  P. Ward,et al.  Oral oseltamivir treatment of influenza in children , 2001, The Pediatric infectious disease journal.

[37]  Tanja Popovic,et al.  Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009. , 2009, MMWR. Morbidity and mortality weekly report.

[38]  G. Boivin,et al.  Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. , 2007, Antiviral research.

[39]  L. Gubareva,et al.  Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. , 2004, Virus research.

[40]  A. Boibieux.  Virus Influenza A(H1N1) 2009 et résistance à l’oseltamivir , 2010 .

[41]  F. Hayden,et al.  Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. , 2006, The Journal of infectious diseases.

[42]  M. Kiso,et al.  Enhanced Expression of an α2,6-Linked Sialic Acid on MDCK Cells Improves Isolation of Human Influenza Viruses and Evaluation of Their Sensitivity to a Neuraminidase Inhibitor , 2005, Journal of Clinical Microbiology.